Plasma Kallikrein Inhibitors: Uses, Common Brands, and Safety Info
"Plasma Kallikrein Inhibitors: Uses, Brands, and Safety. These medications are primarily used for treating hereditary angioedema attacks. Common brands include Takhzyro and Kalbitor. They work by blocking the activity of plasma kallikrein, reducing the frequency and severity of attacks. Side effects are generally mild, including injection site reactions. Precautions should be taken for allergies and drug interactions, and serious allergic reactions are rare. Consultation
Plasma kallikrein inhibitors are a class of medications primarily used for the treatment of hereditary angioedema (HAE) attacks. Hereditary angioedema is a rare genetic disorder that leads to recurrent episodes of swelling in various body parts, including the face, hands, feet, and abdomen. These inhibitors work by blocking the activity of plasma kallikrein, an enzyme that plays a key role in the formation of bradykinin, a substance responsible for triggering the swelling characteristic of HAE attacks. By inhibiting plasma kallikrein, these drugs help reduce the frequency, severity, and duration of HAE attacks.
There are currently two FDA-approved plasma kallikrein inhibitors: lanadelumab (brand name Takhzyro) and ecallantide (brand name Kalbitor). These medications are available by prescription and should only be used under the guidance and supervision of a healthcare professional specialized in the treatment of HAE.
Plasma kallikrein inhibitors are generally safe when used as prescribed by healthcare professionals. However, like any medication, they carry certain risks. Common side effects associated with plasma kallikrein inhibitors include injection site reactions, such as redness, swelling, or pain. These reactions are typically mild and resolve on their own. It is important to inform your healthcare provider about any existing medical conditions or allergies before starting treatment with plasma kallikrein inhibitors. It is also crucial to disclose all other medications, including over-the-counter drugs, herbal supplements, and vitamins, as they may interact with these inhibitors. While rare, serious allergic reactions may occur with the use of plasma kallikrein inhibitors. Signs of an allergic reaction may include difficulty breathing, swelling of the face or throat, rash, or hives. If any of these symptoms occur, immediate medical attention should be sought. Pregnant individuals and breastfeeding mothers should consult their healthcare providers before using plasma kallikrein inhibitors, as the safety of these medications during pregnancy and lactation has not been well-established. In conclusion, plasma kallikrein inhibitors are a valuable class of medications used to manage hereditary angioedema attacks. By inhibiting plasma kallikrein, these drugs help reduce the severity and duration of HAE episodes. It is important to follow the guidance of healthcare professionals when using plasma kallikrein inhibitors and to report any adverse reactions to ensure the safe and effective management of this condition.